




RealRate

PHARMACEUTICAL 2022

LANDEC CORP \CA\
Rank 124 of 475

LANDEC



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of LANDEC CORP \CA\ are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LANDEC CORP \CA\ compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 494% points. The greatest weakness of LANDEC CORP \CA\ is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 437% points.

The company's Economic Capital Ratio, given in the ranking table, is 23%, being 300% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	148,321
Cost of Goods Sold	462,687
Intangible Assets	69,386
Liabilities, Current	101,888
Liabilities, Non-Current	168,501
Other Assets	105,658
Other Compr. Net Income	1,450
Other Expenses	26,927
Other Liabilities	29,751
Other Net Income	-11,626
Property and Equipment	179,559
Research and Development	10,222
Revenues	544,161
Selling, General and Administrative Expense	65,364

Output Variable	Value in 1000 USD
Assets	502,924
Liabilities	300,140
Expenses	565,200
Stockholders Equity	202,784
Net Income	-32,665
Comprehensive Net Income	-31,940
Economic Capital Ratio	23%